Frequently Asked Question:
The global nonalcoholic steatohepatitis (NASH) treatment market was valued at USD 2.2 Billion in 2022.
The nonalcoholic steatohepatitis (NASH) treatment market is anticipated to grow at a CAGR of 62.9% between 2023 and 2030, reaching USD 66.96 Billion in 2030.
Vitamin E & pioglitazone is the leading segment by drug type, holding over 62% share in terms of value in 2022.
The hospital pharmacies segment governs the demand for nonalcoholic steatohepatitis (NASH) treatment worldwide, holding a massive share of over 58% in 2022.
The obeticholic acid (OCA) segment will post the highest CAGR in the projected period.
North America is fueling the growth of the nonalcoholic steatohepatitis (NASH) treatment industry, with an over 40% share in 2022.
The top players include Intercept Pharmaceuticals, AbbVie Inc, Gilead Sciences Inc, and NGM Biopharmaceuticals Inc. Other key players include Galmed Pharmaceuticals, Galectin Therapeutics Inc, Bristol Myers Squibb, and Novo Nordisk A/S.
The increasing prevalence of nonalcoholic steatohepatitis (NASH) worldwide, rising awareness and diagnosis rates, growing R&D activities for novel therapeutics, and favorable government initiatives and regulatory support for NASH treatment are the major market drivers of the NASH treatment industry.
The lack of approved drugs expressly indicated for NASH treatment, high development costs and risks associated with clinical trials, and the potential for adverse events and safety concerns related to NASH therapeutics are the major market restraints of the nonalcoholic steatohepatitis (NASH) treatment industry.
The main market opportunities of the nonalcoholic steatohepatitis (NASH) treatment industry include the development of innovative therapies and drugs, increasing investments in research and development, and the growing awareness and diagnosis of NASH worldwide.